

*XRCC2 R188H (rs3218536), XRCC3
T241M (rs861539) and R243H
(rs77381814) Single Nucleotide
Polymorphisms in Cervical Cancer Risk*

**Luis Orlando Pérez, Andrea Crivaro,
Gisela Barbisan, Lucia Poleri & Carlos
Daniel Golijow**

Pathology & Oncology Research
Official Journal of the Arányi Lajos
Foundation

ISSN 1219-4956

Pathol. Oncol. Res.
DOI 10.1007/s12253-013-9616-2



Your article is protected by copyright and all rights are held exclusively by Arányi Lajos Foundation. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your work, please use the accepted author's version for posting to your own website or your institution's repository. You may further deposit the accepted author's version on a funder's repository at a funder's request, provided it is not made publicly available until 12 months after publication.

XRCC2 R188H (rs3218536), XRCC3 T241M (rs861539) and R243H (rs77381814) Single Nucleotide Polymorphisms in Cervical Cancer Risk

Luis Orlando Pérez · Andrea Crivaro · Gisela Barbisan · Lucia Poleri · Carlos Daniel Golijow

Received: 25 April 2012 / Accepted: 20 February 2013
© Arányi Lajos Foundation 2013

Abstract Human Papillomavirus (HPV) is the main cause of cervical cancer and its precursor lesions. Transformation may be induced by several mechanisms, including oncogene activation and genome instability. Individual differences in DNA damage recognition and repair have been hypothesized to influence cervical cancer risk. The aim of this study was to evaluate whether the double strand break gene polymorphisms XRCC2 R188H G>A (rs3218536), XRCC3 T241M C>T (rs861539) and R243H G>A (rs77381814) are associated to cervical cancer in Argentine women. A case control study consisting of 322 samples (205 cases and 117 controls) was carried out. HPV DNA detection was performed by PCR and genotyping of positive samples by EIA (enzyme immunoassay). XRCC2 and 3 polymorphisms were determined by pyrosequencing. The HPV-adjusted odds ratio (OR) of XRCC2 188 GG/AG genotypes was OR=2.4 (CI=1.1–4.9, $p=0.02$) for cervical cancer. In contrast, there was no increased risk for cervical cancer with XRCC3 241 TT/CC genotypes (OR=0.48; CI=0.2–1; $p=0.1$) or XRCC3 241 CT/CC (OR=0.87; CI=0.52–1.4; $p=0.6$). Regarding

XRCC3 R243H, the G allele was almost fixed in the population studied. In conclusion, although the sample size was modest, the present data indicate a statistical association between cervical cancer and XRCC2 R188H polymorphism. Future studies are needed to confirm these findings.

Keywords Cervical cancer · HPV · XRCC2 · XRCC3 · Single Nucleotide Polymorphism

Introduction

It is widely accepted that infection with Human Papillomavirus (HPV) is the leading cause of cervical cancer. However, HPV infection is very common and in most women it clears up naturally in about 8–12 months. It is estimated that less than 1 % of HPV positive women will progress to severe dysplasia or cervical cancer [1]. The combination of factors that predispose to neoplasia in infected tissue is poorly understood. Much effort has been given to HPV and environmental factors, but the role of host susceptibility to cervical carcinogenesis remains largely unknown.

Studies performed on biological and adoptive sisters of cancer patients identified that development of cervical cancer depends, to a significant extent, on inherited genetic factors [2]. Among these, variants of DNA repair genes are frequently correlated with a higher risk of several human solid tumors. We [3] and others [4–6] have explored polymorphisms in excision nucleotide genes that could be involved in cervical cancer susceptibility. Here, we expand our evaluation to DNA double strand break (DSB) repair polymorphisms in XRCC3 and XRCC2 genes. These genes share essential roles in homologous recombination (HR), a key repair pathway by which somatic cells maintain genome integrity following DNA replication [7].

L. O. Pérez (✉) · A. Crivaro · G. Barbisan · L. Poleri · C. D. Golijow
IGEVEVET-CONICET (Institute of Veterinary Genetics-National Council of Scientific and Technical Investigations), Faculty of Veterinary Genetics, University of La Plata,
60th and 118th Street, PC B1900,
La Plata, Buenos Aires, Argentina
e-mail: perezlo@gmail.com

A. Crivaro
e-mail: andrea.crivaro@gmail.com

G. Barbisan
e-mail: gbarbisanla@yahoo.com

L. Poleri
e-mail: Luciapoleri@gmail.com

C. D. Golijow
e-mail: cgolijow@fcv.unlp.edu.ar

Previous studies have shown that genomic instability is a crucial event in HPV associated cancers, with a significant increase in single and double strand breaks [8, 9]. Experimental data also suggest that chromosomal aberrations may be the result of viral onco-proteins action [10, 11]. In this sense, introduction of HPV E6 and E7 proteins in keratinocytes increased the number of cells with phosphorylated histone H2AX, a marker of DSB damage [12]. Current analyses show that replication of integrated HPV may induce local rearrangements within the integration locus, activating DNA damage checkpoints and recruiting HR proteins [13, 14]. These findings led us to speculate that polymorphisms in HR genes may be directly involved in cervical cancer risk.

Some of the XRCC2 and XRCC3 single nucleotide polymorphisms (SNPs) have been related to human cancers. A G-A substitution at codon 188 of XRCC2, which changes Arg for His (c.563 G>A; rs3218536), may carry a small but significant risk to colorectal [15] and breast cancer [16–18]. While these associations need to be evaluated in larger studies, the substitution is located in a conservative amino acid that does not belong to any known functional motive [16]. Another relevant variant is XRCC3 T241M (exon 7, c.722C>T, rs861539), which several authors have associated with breast cancer [15, 18]. In support of this line, mammalian cells transfected with XRCC3 241M led to a slightly but significance resistance to DSB inducers in relation to the wild type [19]. However, the association between rs861539 and cervical cancer is inconclusive [6, 20–22].

Material and Methods

A total of 322 cervical samples were collected from women attending public hospitals that were part of an anonymous specimen data bank in La Plata, Argentina. Samples corresponded to 205 normal cytologies and 117 squamous cervical cancers. Cervical exfoliated cells from the ecto-endocervix were collected using a cytobrush or spatula. Samples were eluted in 5 ml of phosphate-buffered saline (PBS), pelleted, and kept frozen at -80°C . Biopsy specimens were fixed in formalin and paraffin-embedded and kept at room temperature.

DNA Extraction

Paraffin-embedded samples were washed twice with xylol and finally with 100 % ethanol, re-suspended in 350 μl of proteinase K digestion buffer (250 mg/ml), and incubated for 2 h at 56°C . Cervical exfoliated cell pellets and frozen biopsies were suspended and washed twice with 1 ml of PBS, and incubated for 24 h at 56°C in 400 μl of digestion (extraction) buffer (50 mM Tris-ClH pH 8.5; 1 mM EDTA; 1 % Triton

3100 and 0.5 % Tween 20) containing 250 mg/ml of proteinase K (Promega). After proteinase digestion, samples were boiled for 10 min at 100°C . DNA purification was conducted by the Salting out (direct protein precipitation methodology) procedure [23]. Finally, the DNA was (re)suspended in distilled water and stored at -20°C .

HPV Genotyping

HPV DNA was detected by nested PCR using two rounds of amplification, yielding a 150 bp PCR amplicon that includes a conserved sequence of the viral genome. The primers for first round were MY09/11 [24], and for the second round GP 05/06+ [25]. GP06 primers were biotinylated for later PCR enzyme immune assay [26]. Protocol and cycling conditions for DNA amplification were described elsewhere [3]. PCR products were electrophoresed in 2 % agarose gels, stained with SaferGreenTM (Invitrogen) and visualized in blue light by SafelMagerTM (Invitrogen).

PCR EIA

Briefly, 5 μL of the positive amplicons was captured on streptavidin-coated Maxi Sorp wells (Nunc, Thermo Fisher Scientific, Rochester, NY). The biotin labeled Gp was denatured with 0.2N Na(OH) at room temperature for 30', washed three times (0.25 \times standard saline citrate, 20 % Tween 20) and hybridized with fluorescein-labeled oligoprobes corresponding to HPV types: 6, -11, -16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, and -66. The plate was incubated for 20 min at 60°C with 5 pmol of each probe per 100 μL hybridization buffer (5 \times standard saline citrate, 20 % Tween 20). After a washing step, samples were incubated for 30 min with anti-fluorescein monoclonal antibodies (1:1000) (Millipore, Billerica, MA). After two additional washing steps, the reaction was revealed with 1-Step Turbo TMB-ELISA (Pierce Biotechnology, Rockford, IL). Coloring was stopped after 10 min by 1 M sulfuric acid and the optical density of the color reaction was measured by spectrophotometry (BioRad) at 405 nm.

Amplification and Pyrosequencing of XRCC2 R188H (rs3218536) and XRCC3 T241M (rs861539), R243H (rs77381814) Polymorphisms

The XRCC2 and XRCC3 primers were designed with FastPCR software (Primer Digital Ltd, Finland) version 6.1.55. The XRCC2 R188H primers delimited a region of 151 bp (forward, XRCC227370-90 5'-CTG GAT AGA CCG CGT CAA TGG-3'; reverse, BioX2-27501-21, biotin-5'-ATG

AGC TCG AGG CTT TCT GCA-3'). Each PCR mix contained 0.5 μ M of forward and reverse primers; 2 mM of each dNTP; 2 mM Cl_2Mg ; 1 \times PCR buffer (ClK 500 mM; Tris.ClH 100 mM; pH 9.0; Triton 100 1 %), 1 unit of Taq DNA polymerase (Inbio, Argentina) and 5 μ L of DNA sample in a total volume of 50 μ L. Cycling program was carried out with an initial denaturing step of 92 $^{\circ}\text{C}$ for 3 min, followed by 35 cycles of 30 s at 92 $^{\circ}\text{C}$, 30 s at 60 $^{\circ}\text{C}$, and 45 s at 72 $^{\circ}\text{C}$, with a final elongation step of 72 $^{\circ}\text{C}$ for 5 min.

The XRCC3 primers delimited a region of 152 bp (forward, XRCC31742-62, 5'-CTC ACC TGG TTG ATG CAC AGC-3'; reverse, X3-241-Piro, biotin-5'-TGG TCA TCG ACT CGG TGG CAG-3'). An additional XRCC3 polymorphism, R243H (rs77381814), was also genotyped due to proximity to T241M (rs861539). Each PCR mix contained 0.5 μ M of forward and reverse primers; 2 mM of each dNTP; 1 mM Cl_2Mg ; 1 \times PCR buffer (ClK 500 mM; Tris.ClH

100 mM; pH 9.0; Triton 100 1 %), 1 unit of Taq DNA polymerase (Inbio, Argentina), 5 μ L of DNA sample in a total volume of 50 μ L. Cycling program was carried out with an initial denaturing step of 92 $^{\circ}\text{C}$ for 3 min, followed by 35 cycles of 30 s at 92 $^{\circ}\text{C}$, 50 s at 59 $^{\circ}\text{C}$, and 45 s at 72 $^{\circ}\text{C}$, with a final elongation step of 72 $^{\circ}\text{C}$ for 5 min.

The obtained PCR products were electrophoresed in agarose gel (2 %), stained with SaferGreen and visualized in blue light by SafeImager (Invitrogen). Twenty five micro-liters of each positive PCR product was transferred to 96-wells microplate and sequenced by Pyrosequencing PSQ96 HS System (Biotage, Uppsala, Sweden) according to manufacturers' instructions. The sequencing primer for XRCC2 was: XR2-188-Int, 5'-TTG TAA ATG ACT ATC-3', and nucleotide dispensation order was: TAGACTGTC. The internal primer for XRCC3 was XR3-241-Int, 5'-GGC ACT GCT CAG CTC-3' and could detect both XRCC3 T241M (rs861539)




Fig. 1 Experimental pyrogram patterns for analysis of: **a** XRCC2 188 AA; **b** XRCC2 188 GG; **c** XRCC3 241 TT and 243 GG; **d** XRCC3 241 CC and 243 GA; **e** XRCC3 241 TC and 243 GG (Note that XRCC3 sequence in pyrograms is complementary to consensus)

Table 1 Genotype distribution of XRCC2 R188H and XRCC3 T241M variants in cases and controls

		Cases		Controls	Odds ratio (IC _{95%})(P)	Odds ratio ^a (IC _{95%}) (P)
XRCC2 R188H	GG	106	165		2.3 (1.1–4.7) (0.019)	2.4 (1.1–4.9) (0.02)
	AG	11	40		Reference	Reference
XRCC3 T241M	TT	11	32		0.53 (0.24–1.16) (0.11)	0.48 (0.2–1) (0.1)
	CT	56	95		0.92 (0.56–1.49) (0.73)	0.87 (0.52–1.4) (0.6)
	CC	50	78		Reference	Reference

^aHPV-adjusted odds ratio

and R243H (rs77381814) SNPs. The nucleotide dispensation order for this reaction was: GACTAGCAGCGA. Representative pyrograms for XRCC2 and XRCC3 SNPs are shown in Fig. 1.

Statistical Analysis

Statistical associations were assessed by the chi-square test, *p* values were two sided, and significance was set at *p*<0.05. For risk estimation, odds ratios and 95 % confidence interval were obtained by binary logistic regression using the SPSS software (SPSS Inc).

Results

Overall HPV DNA was detected in 39 % (80/205) of controls and 67 % (78/117) of cases. According to our methodology, the distribution of HPV types among the positive samples showed that 29 % of detection in controls and 50 % in case subjects belonged to high-risk types. HPV 16 was the prevalent type in control subjects (55 %), followed by HPV 18 (18.9 %), HPV 11 (9.4 %), HPV 6 (5.4 %), HPV 31 (4 %) and HPV 33 (1.3 %) Similar results were obtained for case patients: HPV 16 was the prevalent type (65.7 %), followed by HPV18 (10 %), HPV 31 (5.7 %), HPV 33 (4.2 %), HPV 11 (2.8 %) and HPV 45 (1.4 %). Co-infection frequency was low;

among HPV positive samples 15.6 % of controls and 7.8 % of cases had more than one infection.

The allele and genotypes frequencies of XRCC2 R188H (rs3218536) and XRCC3 T241M (rs861539) polymorphisms are shown in Table 1. All genotype distributions of controls were consistent with the Hardy Weinberg equilibrium (*p*=0.16 for rs3218536 and *p*=0.4 for rs861539). For the additional XRCC3 243 polymorphism (rs77381814), the GG genotype was almost fixed in the population, with the exception of one control GA. Figure 1 depicts the obtained pyrograms for the resulting genotypes. The comparison between XRCC genotypes and HPV types revealed no association between infection and polymorphism (Table 2). Viral types were divided in low and high risk groups in order to provide sufficient statistical power.

Binary logistic regression was used to calculate odds ratios for cervical cancer risk. The allele frequency of XRCC2 188 G (rs3218536) was slightly higher in cases (0.95) than controls (0.91), but the difference was statistically significant (*p*=0.023). In this sense, the homozygous 188 GG genotype was associated with an increasing risk for cervical cancer (OR=2.3; CI=1.1–4.7; *p*=0.019) when compared with XRCC2 188 AG. It is noteworthy that we did not find any individual carrying the XRCC2 188 AA genotype. On the other hand, the distribution of XRCC3 241 (rs861539) genotypes remained similar between cases and controls. In this sense, the allele frequency of XRCC3241 C was similar in controls (0.61) and cases (0.66).

Table 2 Distribution of XRCC genotypes among women infected with low-risk and high-risk HPV types

HPV	XRCC2 R188H						XRCC3 T241M							
	Controls		<i>P</i> value	Cases		<i>P</i> value	Controls			<i>P</i> value	Cases			<i>P</i> value
	AG	GG		AG	GG		CC	CT	TT		CC	CT	TT	
Neg	25	100		2	37		51	59	15		17	16	6	
Low-risk ^a	4	18	0.8 NS	2	18	0.9 NS	6	9	7	0.9 NS	12	8	0	0.77 NS
High-risk ^b	11	47	0.8 NS	7	51	0.4 NS	21	27	10	0.9NS	21	32	5	0.43 NS

NS Non significant

^a HPV 6, 11, 42

^b HPV 16, 18, 31, 33, 45

Discussion

The role of DNA repair genes on the risk of human cancers is being increasingly recognized. Genetic instability is a common feature of human tumors and recent evidence suggests that mutations in DNA repair genes are implicated in both initiation and cancer progression. Whereas mutations in high penetrance genes such as the breast cancer genes BRCA1 and 2 are less frequent, there are low penetrance polymorphisms that may explain the remaining risk. In this sense, single nucleotide polymorphisms of DNA repair genes are extensively studied in breast and ovarian cancer. Here, we present evidence that supports that XRCC2 R188H (rs3218536) polymorphism may be associated with cervical cancer.

The frequency of the XRCC2 188 A allele found in this study was lower than those reported from Europe [16, 27] and the US [28]. To the best of our knowledge, this is the first study examining the XRCC2 188 G>A variant in cervical cancer. A meta-analysis performed by Vineis et al. [8] with data collected from 1985 to 2007 showed that XRCC2 188 A confers a slightly but significantly risk for colorectal cancer. Other authors have associated XRCC2 A with breast and ovarian cancer, but the association remains controversial [16, 27, 29, 30]. Contrary to most cancers studied so far, we found that the risk allele associated with cervical cancer was G, not A. Although there is needed more studies to assess this relation, an intriguing issue is raised as to whether XRCC2 188 G>A has a different role in cervical cancer, probably by identifying HPV induced DNA damage in host genome or by playing a part in viral integration [22].

Despite speculations, few active sites have been demonstrated for the XRCC2 gene and codon 188 (rs3218536) does not lie within any of them. Rafii et al. [16] have shown that XRCC2 is able to form complexes with certain RAD51 paralogs, therefore functional motives remain to be identified. It is also possible that cancer association is not directly linked to codon 188, but to another SNP located inside the Walker motive (ATPase). Similar to this, XRCC3 T241M (rs861539) polymorphism modifies an aminoacid that does not lie in a known functional motive, but unlike XRCC2 188 (rs3218536), it has stronger evidence of differential activity between alleles. In this sense, it was shown that this variant responds differentially to certain DSB inducers in CHO cells which were transfected with human variants of XRCC3 [19].

Population studies have shown that the XRCC3 T241M (rs861539) polymorphism was associated with breast cancer [15, 18], although the conferred risk, as other low penetrance genes confers, is relatively low. We failed at finding a significant association between rs861539 and cervical cancer. These results are in agreement with those found by others [20–22]. In agreement, a large case control study

performed in Costa Rica, which analyzed the contribution of DNA repair gene polymorphisms and cervical cancer, did not identify an association between rs861539 and neoplasia. It is noteworthy, however, that in that study HPV persistence was linked to another DNA repair gene variant, XRCC1 codon 399 polymorphism (rs25487) [6].

Despite controversial findings, the link between cervical cancer risk and genetic variants of DNA repair genes remains to be proved. Our results support the view that functional polymorphisms may influence cervical cancer risk. Although the mechanism is unknown, recent data suggest that expression of homologous recombination proteins is actively involved in HPV induced instability. Kazara et al. (2009) demonstrated that chromosomal rearrangements could be triggered by the unscheduled replication of integrated HPV, yielding numerous double strand breaks and exceeding the cellular DNA repair system [12].

In conclusion, our results provide evidence for a statistical association between a genetic polymorphism of XRCC2 and cervical cancer, suggesting that this protein may be specifically involved in repair of HPV related DNA damage. However, larger studies are needed to confirm this hypothesis.

Acknowledgments The authors would like to thank the National Agency of Scientific and Technological Promotion (PICT 01–20149.) for their funding of this research.

Conflict of interest statement We declare that we have no conflict of interest.

References

1. Wright TC (2009) Natural history of HPV infections. *J Fam Pract* 58:3–7
2. Magnusson P, Lichtenstein P, Gyllenstein U (2000) Heritability of cervical tumours. *Int J Cancer* 88:698–701
3. Barbisan G, Pérez LO, Difranza L, Fernández CJ, Ciancio NE, Golijow CD (2011) XRCC1 Arg399Gln polymorphism and risk for cervical cancer development in Argentine women. *Eur J Gynaecol Oncol* 32:274–279
4. Huang J, Ye F, Chen H, Lu W, Xie X (2007) The nonsynonymous single nucleotide polymorphisms of DNA repair gene XRCC1 and susceptibility to the development of cervical carcinoma and high-risk human papillomavirus infection. *Int J Gynecol Cancer* 17:668–675
5. Roszak A, Lianeri M, Jagodzinski PP (2011) Involvement of the XRCC1 Arg399Gln gene polymorphism in the development of cervical carcinoma. *Int J Biol Markers* 26(4):216–220
6. Settheetham-Ishida W, Yuenyao P, Natphosuk S, Settheetham D, Ishida T (2011) Genetic risk of DNA repair gene polymorphisms (XRCC1 and XRCC3) for high risk human papillomavirus negative cervical cancer in Northeast Thailand. *Asian Pac J Cancer Prev* 12:963–966
7. Thacker J (2005) The RAD51 gene family, genetic instability and cancer. *Cancer Lett* 219:125–135
8. Udumudi A, Jaiswal M, Rajeswari N et al (1998) Risk assessment in cervical dysplasia patients by single cell gel electrophoresis assay: a study of DNA damage and repair. *Mutat Res* 30:195–205
9. Cortés-Gutiérrez EI, Dávila-Rodríguez MI, Fernandez JL et al (2011) DNA damage in women with cervical neoplasia evaluated

- by DNA breakage detection-fluorescence in situ hybridization. *Anal Quant Cytol Histol* 33:175–181
10. Duensing S, Munger K (2002) The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. *Cancer Res* 62:7075–7082
11. Kadaja M, Sumerina A, Verst T, Ojarand M, Ustav E et al (2007) Genomic instability of the host cell induced by the human papillomavirus replication machinery. *EMBO J* 26:2180–2191
12. Kadaja M, Sumerina A, Verst T, Ojarand M, Ustav E, Ustav M (2007) Genomic instability of the host cell induced by the human papillomavirus replication machinery. *EMBO J* 26:2180–2191
13. Kadaja M, Silla T, Ustav E, Ustav M (2009) Papillomavirus DNA replication - from initiation to genomic instability. *Virology* 384:360–368
14. Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M (2009) Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. *PLoS Pathog* 5:e1000397
15. Vineis P, Manuguerra M, Kavvoura FK, Guarrera S, Allione A, Rosa F et al (2009) A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. *J Natl Cancer Inst* 101:24–36
16. Raffi S, O'Regan P, Xinarianos G, Azmy I, Stephenson T, Reed M et al (2002) A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. *Hum Mol Genet* 11:1433–1438
17. Loizidou MA, Michael T, Neuhausen SL, Newbold RF, Marcou Y, Kakouri E et al (2008) Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus. *Breast Cancer Res Treat* 112:575–579
18. Romanowicz-Makowska H, Smolarz B, Zadrozny M, Westfal B, Baszczynski J, Polac I, Sporny S (2011) Single nucleotide polymorphisms in the homologous recombination repair genes and breast cancer risk in polish women. *Tohoku J Exp Med* 224:201–208
19. Raffi S, Lindblom A, Reed M, Meuth M, Cox A (2003) A naturally occurring mutation in an ATP-binding domain of the recombination repair gene XRCC3 ablates its function without causing cancer susceptibility. *Hum Mol Genet* 12:915–923
20. De Ruyck K, Van Eijkeren M, Claes K, Morthier R, De Paepe A, Vral A et al (2005) Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. *Int J Radiat Oncol Biol Phys* 15:1140–1149
21. He X, Ye F, Zhang J, Cheng Q, Shen J, Chen H (2008) Susceptibility of XRCC3, XPD, and XPG genetic variants to cervical carcinoma. *Pathobiology* 75:356–363
22. Wang SS, Bratti MC, Rodríguez AC, Herrero R, Burk RD, Porras C et al (2009) Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. *J Infect Dis* 199:20–30
23. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 16:1215
24. Ting Y, Manos MM (1990) Detection and typing of genital human Papillomavirus. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ (eds) PCR protocols. Academic, San Diego, p 356
25. Evander M, Edlund K, Bodun E et al (1992) Comparison of a one-step and two-step polymerase chain reaction with degenerate general primers in a population-based study of human Papillomavirus infection in young Swedish women. *J Clin Microbiol* 30:987–992
26. Söderlund-Strand A, Rymark P, Andersson P et al (2005) Comparison between the Hybrid Capture II Test and a PCR-Based Human Papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. *J Clin Microbiol* 43:3260–3266
27. Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM et al (2002) Variants in DNA double-strand break repair genes and breast cancer susceptibility. *Hum Mol Genet* 11:1399–1407
28. Jiao L, Hassan MM, Bondy ML, Wolff RA, Evans DB, Abbruzzese JL et al (2008) XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. *Am J Gastroenterol* 103:360–367
29. Han J, Hankinson SE, Zhang SM, De Vivo I, Hunter DJ (2004) Interaction between genetic variations in DNA repair genes and plasma folate on breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 13:520–524
30. Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U et al (2009) Validating genetic risk associations for ovarian cancer through the International Ovarian Cancer Association Consortium. *Br J Cancer* 100:412–20, Erratum in: Cunningham JC (2009) *Br J Cancer* 101:1805